The AI Impact Award, presented by the German business newspaper manager magazin and Porsche Consulting, honors companies that successfully and effectively apply artificial intelligence in realworld practice. The award highlights solutions that create genuine economic and societal added value.
The globally active Swiss healthcare company Roche has been nominated for the 2026 AI Impact Award in the Product and Customer Experience category, which recognizes solutions that enhance customer experience while driving profit and revenue growth. In a brief interview, Dr. Imane Moest, Head of Chronic Remote Care at Roche, explains the challenges the team faced, how the AI-driven approach was developed, and what results are already visible today.
Dr. Moest, worldwide, more than 500 million people are affected by diabetes – and the number is rising. Why do the commonly used diabetes monitoring methods on the market often fall short when it comes to reliably controlling glucose levels?
Dr. Imane Moest: Diabetes is a “24/7” job for people living with the condition. The chronic condition often leaves patients in a state of uncertainty about how their glucose levels will change over time. Traditional methods like using blood glucose monitoring devices, or BGMs for short, often only provide snapshots. As a result, dangerous fluctuations may go undetected – especially at night. Increasingly, continuous glucose monitoring technology, known as CGM, is being used. These systems measure blood glucose levels every few minutes, allowing for improved tracking of glucose trends. Yet even when using a CGM system, a clear picture emerges: a significant proportion of people living with diabetes still do not meet their glycemic targets.1 This constant uncertainty can profoundly affect patients’ daily freedom and emotional well-being.